Clinical and Prognostic Value of PET/CT Imaging with Combination of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms

<div>Comparison of SUV<sub>max</sub> of PET/CT according to primary sites ((a) and (b)) and tumor grade ((c) and (d)). The sensitivity of group A (G1 + G2a = Ki-67 &lt; 10%), group B (G2b + G3a = well-differentiated neoplasms with Ki-67 ≥ 10%), and group C (G3b = poorly differentiated neoplasms with Ki-67 &gt; 20%) in PET/CT imaging.</div>

Contrast Media & Molecular Imaging

fig1

Figure 1

Figure 1: Clinical and Prognostic Value of PET/CT Imaging with Combination of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms 

Figure 1 | Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms 